BioTime Inc (BTX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:BioTime Inc (BTX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7122
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company’s aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime’s products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
BioTime Inc, Medical Equipment, Deal Details 12
Partnerships 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
Equity Offering 18
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For US$6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To US$15 Million 35
BioTime Completes Public Offering Of Shares For US$3.5 Million 36
BioTime Completes Private Placement Of Units For US$9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 38
BioTime Announces Private Placement Of Common Stock 40
Acquisition 41
BioIVT Acquires Ascendance Biotech 41
BioTime Inc – Key Competitors 42
BioTime Inc – Key Employees 43
BioTime Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Financial Announcements 46
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 46
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 48
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 50
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 52
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 54
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 56
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 58
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 61
Corporate Communications 62
Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 62
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 63
Feb 26, 2018: BioTime Appoints Gary S. Hogge As Sr. Vice President, Clinical and Medical Affairs 64
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 65
Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67
Product News 68
Aug 16, 2018: BioTime to present data at the Military Health System Research Symposium 68
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69
Other Significant Developments 70
Jan 22, 2018: BioTime Announces 2018 Clinical and Corporate Milestone Targets 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
BioTime Inc, Medical Equipment, Key Facts, 2017 2
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Deals By Market, 2012 to YTD 2018 9
BioTime Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13
OncoCyte Expands Co-Development Agreement with Wistar Institute 14
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16
OncoCyte to Raise USD4 Million in Private Placement of Shares and Warrants 18
OncoCyte Raises USD10 Million in Private Placement of Shares 19
BioTime Completes Public Offering of Shares for USD28.8 Million 20
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 22
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 23
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 24
BioTime to Raise up to USD25 Million in Private Placement of Shares 26
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 27
OncoCyte Raises USD3.2 Million in Private Placement of Units 28
OncoCyte Raises USD7.3 Million in Private Placement of Units 29
BioTime Raises USD5 Million in Private Placement of Shares 30
BioTime Raises USD20.4 Million in Private Placement of Shares 31
OncoCyte Raises USD3.3 Million in Private Placement of Shares 33
BioTime Completes Private Placement Of Shares For US$6.4 Million 34
BioTime Announces Public Offering Of Shares For Up To US$15 Million 35
BioTime Completes Public Offering Of Shares For US$3.5 Million 36
BioTime Completes Private Placement Of Units For US$9 Million 37
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 38
BioTime Announces Private Placement Of Common Stock 40
BioIVT Acquires Ascendance Biotech 41
BioTime Inc, Key Competitors 42
BioTime Inc, Key Employees 43
BioTime Inc, Subsidiaries 44
BioTime Inc, Joint Venture 45

List of Figures
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
BioTime Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
BioTime Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
BioTime Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
BioTime Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[BioTime Inc (BTX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sega Sammy Holdings Inc (6460):企業の財務・戦略的SWOT分析
    Sega Sammy Holdings Inc (6460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Federal Electricity & Water Authority:企業の戦略的SWOT分析
    Federal Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Oracle Corporation:企業の戦略・SWOT・財務情報
    Oracle Corporation - Strategy, SWOT and Corporate Finance Report Summary Oracle Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mgm China Holdings Ltd
    Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Welch Allyn Inc:企業の戦略的SWOT分析
    Welch Allyn Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Intellect Design Arena Limited:戦略・SWOT・企業財務分析
    Intellect Design Arena Limited - Strategy, SWOT and Corporate Finance Report Summary Intellect Design Arena Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Galmed Pharmaceuticals Ltd (GLMD):製薬・医療:M&Aディール及び事業提携情報
    Summary Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company. The company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST …
  • Tivo Corporation:戦略・SWOT・企業財務分析
    Tivo Corporation - Strategy, SWOT and Corporate Finance Report Summary Tivo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Immunogen, Inc.:企業の戦略・SWOT・財務分析
    Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Carlson Inc:企業の戦略・SWOT・財務情報
    Carlson Inc - Strategy, SWOT and Corporate Finance Report Summary Carlson Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sukhoi Company:戦略・SWOT・企業財務分析
    Sukhoi Company - Strategy, SWOT and Corporate Finance Report Summary Sukhoi Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Hitachi Ltd (6501):電力:M&Aディール及び事業提携情報
    Summary Hitachi Ltd (Hitachi) is a multinational company with operations in sectors such as engineering and electronics, nuclear, transportation and industrial systems. It manufactures and sells information and telecommunication systems, power systems, social infrastructure and industrial systems, c …
  • Terramin Australia Ltd:企業の戦略・SWOT・財務情報
    Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Arsenal Medical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Arsenal Medical Inc (Arsenal) is a platform technology company that develops novel therapeutic polymer based foams. The company’s products include in-situ forming materials, in-situ forming polymeric foam and in-situ curing elastomeric polymer material. It offers in-situ forming materials to …
  • Convergys Corporation:企業の戦略・SWOT・財務情報
    Convergys Corporation - Strategy, SWOT and Corporate Finance Report Summary Convergys Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sophiris Bio Inc (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostati …
  • Punch Taverns Plc:企業のM&A・事業提携・投資動向
    Punch Taverns Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Punch Taverns Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Batu Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Batu Biologics Inc (Batu Biologics) is an immuno-oncology company. The company offers development and commercialization of novel therapies that target the Achilles Heel of cancer: the tumor blood vessels. Its lead product ValloVax is a cellular anti-angiogenic cancer vaccine that is develope …
  • Tokyo Broadcasting System Holdings Inc (9401):企業の財務・戦略的SWOT分析
    Tokyo Broadcasting System Holdings Inc (9401) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報
    Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆